Chemoprevention in prostate cancer: The role of difluoromethylornithine (DFMO)

Journal of Cellular Biochemistry

Volumn 50, Issue S16H, 1992, Pages 122-127

  Kadmon, Dov ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

chemoprevention; difluoromethylcrnithine (DFMO); polyamines; prostate carcinoma

Indexed keywords

EFLORNITHINE; POLYAMINE; ORNITHINE DECARBOXYLASE;

CHEMOPROPHYLAXIS; CONFERENCE PAPER; PRIORITY JOURNAL; PROSTATE CANCER; ANIMAL; DRUG ANTAGONISM; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; REVIEW;

ANIMALS; EFLORNITHINE; HUMANS; MALE; ORNITHINE DECARBOXYLASE; POLYAMINES; PROSTATIC NEOPLASMS;

EID: 0027077604     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.240501228     Document Type: Article

References (43)

1. Cancer statistics, 1991
2. Early detection of prostate cancer
3. Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
4. Carcinoma of the prostate
5. Chemotherapy for prostatic carcinoma
6. Latent carcinoma of the prostate
7. The prostate–An increasing medical problem
8. Latency and progression in tumors. The natural histroy of prostatic tumors
9. Latent carcinoma of the prostate at autopsy in seven areas
10. Epidemiologic aspects of latent and clinically manifest carcinoma of the prostate
11. Clinical evidence for and implications of the multistep development of prostate cancer
12. Cancer as a disease of DNA organization and dynamic cell structure
13. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ
14. Genetic alterations during colorectal‐tumor development
15. Proliferative activity of benign human prostate, prostatic adenocarcinoma and seminal vesicle evaluated by thymidine labeling
16. Prostate‐specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients
17. Progress in applied chemoprevention research
18. Role of polyamines in the control of cell proliferation and differentiation
19. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy
20. Molecular genetics of polyamine synthesis in eukaryotic cells
21. Ornithine decarboxylase activity in regenerating rat liver, chick embryo and various tissues
22. Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E.C.4.1.1.17) by substrate and product analogues
23. Effect of α‐difluoromethylornithine, an enzyme‐activated irreversible inhibitor of ornithine decarboxylase, on polyamine levels in rat tissues
24. Spermidine and spermine in rat tissues at different ages
25. Effects of ornithine decarboxylase inhibitors in vivo, enzyme‐activated irreversible inhibitors
26. Effect on prostatic growth of α‐difluoromethylornithine, an effective inhibitor of ornithine decarboxylase
27. Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor alpha‐difluoromethylornithine
28. Potentiation of methylglyoxal‐bis‐guanylhydrazone by alpha‐difluoromethylornithine in rat prostate cancer
29. Ornithine decarboxylase as a biologic marker in familial colonic polyposis
30. Inhibition of mouse skin tumor promotion and of promoter stimulated epidermal polyamine biosynthesis by alpha‐difluoromethylornithine
31. Effects of DL‐α‐difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, on the rat mammary tumor induced by 7,12‐dimethylbenz[a]anthracene
32. Inhibition of mouse skin tumor promotion and of promoter stimulated epidermal polyamine biosynthesis by alpha‐difluoromethylornithine
33. Inhibition of intestinal carcinogenesis in rats: Effect of difluoromethyl‐ornithine with piroxicam or fish oil
34. Inhibition of ornithine decarboxylase with 2‐difluoromethlyornithine: Reduced incidence of dimethylhydrazine‐induced colon tumors in mice
35. Effect of inhibition of polyamine biosynthesis by DL‐α‐difluoromethylornithine on the growth and melanogenesis of B16 melanoma in vitro and in vivo
36. Induction of F9 embryonal carcinoma cell differentiation by inhibition of polyamine synthesis
37. Phase II trials of α‐difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer
38. A phase II study of α‐difluoromethylornithine (DFMO) for the treatment of metastatic melanoma
39. Alterations in bone marrow and blood mononuclear cell polyamine and methylglyoxal bis(guanylhydrazone) levels: Phase I evaluation of α‐difluoromethylornithine and methylglyoxal bis(guanylhydrazone) treatment of human hematological malignancies
40. Chemotherapy of primary brain tumors
41. Inhibition of ornithine decarboxylase activity by small doses of α‐difluoromethylornithine
42. Chemoprevention and chemotherapy by inhibition of ornithine decarboxylase activity and polyamine synthesis: Colonic, pancreatic, mammary and renal carcinomas
43. Long‐term maintenance therapy of established human small cell variant lung carcinoma implants in athymic mice with a cyclic regimen of difluoromethylornithine